Gel4Med is harnessing the power of smart materials to address the greatest challenges in medicine.
Gel4Med is a commercial-stage company utilizing bioinspiration and materials engineering to solve the most significant challenges in medicine.
Founded out of the Harvard Innovation Labs at Harvard University, Gel4Med is utilizing its Smart Materials Platform™ technology to solve unmet clinical needs. In October 2023, the company received their first FDA 510(k) market clearance on G4Derm™/G4Derm™ Plus, Gel4Med's lead asset directed at wound care and surgical reconstruction.
At Gel4Med, we are committed to enhancing health outcomes and access to all patients by creating advanced medical solutions through the development of novel biomaterials.
Gel4Med’s proprietary Smart Materials Platform (SMP™) is an innovative, patented bioengineering approach for developing therapeutics and devices to address a wide range of clinical needs.
G4Derm™ Plus is a novel flowable biomimetic matrix derived from Gel4Med’s SMP™ technology to manage complex wounds.
Learn more
Gel4Med, an innovative biomaterials company, is proud to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its first biosynthetic matrix products...
Learn more
Gel4Med and the University of Miami funded to collaborate and innovate around novel treatments for Spinal Cord Injury.
Learn more
Gel4Med has been awarded significant funding from the highly competitive National Institutes of Health Commercial Readiness Pilot (CRP) program!
Learn more
"As a result of its intentionally engineered design using self-assembling peptides, the G4Derm™ product line offers a unique materials science approach to product development that has the potential to transform the wound care and surgical reconstruction industry."
1660 Soldiers Field Road,
STE 7, #1063
Brighton MA 02135
M2D2 Umass Lowell, 110 Canal St, 4th Floor, Lowell MA 01852